Table 4.
Simulation results, table values description in the results paragraph.
| Model parameter | Baseline (N = 43) | Last 5 years (N = 40) | Medicated only (N = 33) | p | |||
|---|---|---|---|---|---|---|---|
| Simulation | Absolute | Simulation | Absolute | Simulation | Absolute | ||
| output SUM | contribution % | output SUM | contribution % | output SUM | contribution % | ||
| (dimensionless) | (dimensionless) | (dimensionless) | |||||
| Anxiety | −5,264, 94 | 4, 6% | −7,695, 29 | 5, 1% | −2,127, 76 | 6, 3% | 0.111 |
| Depression | −1,468, 65 | 1, 3% | −1,936, 36 | 1, 3% | −519, 98 | 1, 5% | 0.345 |
| Sleep inertia | −23,785, 71 | 20, 7% | −31,467, 42 | 20, 8% | −7,561, 71 | 22, 3% | 0.48 |
| Work and social | −19,854, 40 | 17, 3% | −22,906, 08 | 15, 2% | −2,865, 86 | 8, 5% | 0.004 |
| impairment | |||||||
| Sleepiness | −12,983, 30 | 11, 3% | −17,127, 30 | 11, 3% | −3,760, 46 | 11, 1% | 0.028 |
| Fatigue | −5,885, 17 | 5, 1% | −9,196, 22 | 6, 1% | −3,168, 03 | 9, 3% | 0.345 |
| Naps | 19,689, 76 | 17, 2% | 26,442, 19 | 17, 5% | 5,941, 81 | 17, 5% | 0.028 |
| Nocturnal sleep | 17,099, 39 | 14, 9% | 22,418, 76 | 14, 8% | 4,535, 73 | 13, 4% | 0.008 |
| Other psychiatric | −1,502, 53 | 1, 3% | −1,954, 41 | 1, 3% | −550, 40 | 1, 6% | 0.345 |
| disorders | |||||||
| Somatic pathologies | −4,773, 05 | 4, 2% | −5,924, 73 | 3, 9% | −1,077, 70 | 3, 2% | 0.004 |
| Methylphenidate | 1,109, 83 | 1, 0% | 1,768, 80 | 1, 2% | 782, 93 | 2, 3% | 0.421 |
| effect | |||||||
| Modafinil effect | 1,254, 81 | 1, 1% | 2,244, 32 | 1, 5% | 1,014, 49 | 3, 0% | 0.5 |
| Sum % | 100% | 100, 0% | 100, 0% | ||||
Negative results in the simulation output SUM column indicate a negative effect of the parameter and vice versa. The baseline scenario covers all patients for the entire duration of the disease. The last 5 years scenario focuses on the last 5 years; the number of patients in the cohort is reduced by one because the disease, in that case, lasted only 1 year. The medicated only scenario describes the set of medicated patients in the last 5 years of disease duration, regardless of the length of medication and clinical outcomes.